What the European Union can Teach the US About Health Technology Assessment Harmonization
Health Technology Assessment (HTA) in the US is a convoluted piecemeal process where each payer performs their own assessments without [...]
Gene Therapy for Beta Thalassemia Gene Under ICER Assessment
A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from [...]
Value-based Analysis of Telehealth in the US
Telehealth has rapidly expanded in recent years and is offered by up to 60% of care providers. This increase is [...]
Are Mammograms After 75 Worth It?
Uncertainty is building regarding the value of mammograms for breast cancer screening after 75 years of age according to a [...]
Establishing the Value of Next-Gen Sequencing
Next-generation sequencing (NGS) has been touted by some as the backbone of future precision medicine approaches. This technology could help [...]
ISPOR Boosts HEOR in Low & Middle-Income Countries
ISPOR pledged to promote HEOR efforts in low- to middle-income countries (LMICs) in its Strategic Plan 2024. LMICs often face [...]
Reference Pricing Could Negatively Affect Vulnerable Populations
Some countries use QALYs (Quality-Adjusted Life Years) to assess whether or not to use a treatment or prescription drug. The [...]
The Problem With Discriminatory Value Assessments
By utilizing discriminatory value assessments, foreign governments like in the U.K., have created barriers to care for individuals w/ disabilities [...]
Value Assessment in the Context of COVID-19
Efforts to rapidly respond to the coronavirus pandemic have highlighted the need for credible, relevant, and timely information on the [...]
[Webinar] Multi-Criteria Decision Analysis: Can It Help Make Value Assessment More Patient-Centered?
Researchers, value assessors, and the patient community agree that traditional means of value assessment often do not factor in the [...]
How Will Innovation Value be Redefined in 2021?
The health policy landscape will most certainly be altered in 2021 as a result of the US Presidential election. No [...]
[Webinar] Value Assessment in the Age of COVID-19
ISPOR, the Innovation and Value Initiative (IVI), and a panel of distinguished experts collaborate in this webinar series to define [...]
The QALY and Value Assessment Frameworks in the Asia-Pacific Context
Although the QALY (quality-adjusted life year) has been a useful metric over the past few decades, it is not without [...]
Innovation and Value Initiative’s (IVI) Jennifer Bright on Value Assessment and Transparency
Jennifer Bright is Executive Director of the Innovation and Value Initiative (IVI), a non-profit organization whose mission is to to [...]
[Webinar] Value Assessment in the Age of COVID-19: Meeting the Challenges
An important discussion is developing around Value Assessment (VA) and Health Technology Assessment (HTA) as COVID-19 intensifies challenges to effectively [...]
ISPOR Short Course on Medical Devices is Tomorrow
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) short course on market access and value assessment of medical devices [...]
PhRMA Foundation Extends Deadline on Applications for Value Assessment Awards
The PhRMA Foundation announced an extended application deadline for the foundation's 2020 Value Assessment Awards. Applications are due July 15. [...]
ISPOR Offering Short Courses on Value Assessment Frameworks, HTA
The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) is offering two short, online courses. Below are the two courses: [...]
PRMA’s Lodowski Highlights 2020 Updates to ICER’s Value Assessment Framework
PRMA Consulting's Nicole Lodowski in a recent blog post outlines seven key areas that have been updated in the Institute [...]
Garrison, Howard Discuss Future of Value Assessment
The American Journal of Managed Care (AMJC) recently interviewed two panelists set to discuss the future of value assessment during [...]
Experts: Including Productivity in Value Assessment Frameworks Can Make Difference
The National Pharmaceutical Council (NPC) in a recent study published in JAMA suggests including productivity in value assessments can have [...]
Study: Value Assessments Should Factor Full Range of Costs, Benefits
A recent study published in JMCP suggests value assessments should capture the full range of costs and benefits associated with [...]
Report: Value Assessments Should Include Employer-Relevant Elements
A recent report by the National Alliance of Healthcare Purchaser Coalitions found that the lack of employer-relevant elements in value [...]
Blog Post Mulls Indirect Benefits in Value Assessments
A recent blog post published on Health Affairs highlights some key reasons why indirect benefits should be factored into value [...]
Tufts’ Cohen Highlights ICER’s Third Value Assessment Framework
Tufts Medical Center's Joshua Cohen, deputy director of the Center for the Evaluation of Value and Risk in Health, in [...]
